- Home
- CTNM
as 06-20-2025 4:00pm EST
Stocks
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.
| Founded: | 2009 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 122.9M | IPO Year: | 2024 |
| Target Price: | $22.50 | AVG Volume (30 days): | 119.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.98 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.35 - $22.00 | Next Earning Date: | 08-12-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Contineum Therapeutics Inc. Class A Common Stock News
CTNM Breaking Stock News: Dive into CTNM Ticker-Specific Updates for Smart Investing
MT Newswires
a day ago
William Blair Initiates Coverage on Contineum Therapeutics With Outperform Rating
Simply Wall St.
18 days ago
Discover Real Brokerage And 2 Other Penny Stocks To Watch
Business Wire
a month ago
Contineum Therapeutics to Present at the 2025 RBC Capital Markets Global Healthcare Conference
Business Wire
a month ago
Contineum Therapeutics Reports First-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones
Business Wire
2 months ago
Contineum Therapeutics Appoints Timothy Watkins, M.D., M.Sc., as Chief Medical Officer and Head of Development
Simply Wall St.
2 months ago
We're Not Very Worried About Contineum Therapeutics' (NASDAQ:CTNM) Cash Burn Rate
Business Wire
3 months ago
Contineum Therapeutics Announces Appointment of Diego Miralles, M.D. to Its Board of Directors
Simply Wall St.
3 months ago
Institutional investors in Contineum Therapeutics, Inc. (NASDAQ:CTNM) have had a wonderful week after share price increased 24%
Compare CTNM vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CTNM Contineum Therapeutics Inc. Class A Common Stock - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.